No Data
No Data
Biocause Pharmaceutical's Insurance Arm Accumulates 35 Billion Yuan in 2024 Insurance Premium Income
A-share large financial stocks showed a sudden surge in the morning, with ChinaLin Securities hitting the daily price limit.
On December 23, Gelonghui reported that ChinaLin Securities surged to the daily limit, with Hubei Biocause Pharmaceutical, Bank Of Ningbo, Guosen, Shanghai Pudong Development Bank, Ping An Insurance, and others following suit.
Express News | Hubei Biocause Pharmaceutical: CHINA BEST's premium income for 2024 is approximately 32.694 billion yuan.
A-shares in the Insurance sector decline, Hubei Biocause Pharmaceutical falls over 8%.
On December 11, GF Securities reported that Hubei Biocause Pharmaceutical fell by over 8%, with New China Life Insurance, The People's Insurance, China Life Insurance, and China Pacific Insurance also following the decline.
The A-shares financial stocks surged, with shanghai dzh limited hitting the ceiling.
On December 10, Gelonghui reported that shanghai dzh limited hit the upper limit, hubei biocause pharmaceutical, guosheng financial holding inc., and jiangxi tianli technology, inc. previously reached the upper limit, while sgsg science&technology, beijing compass technology development, shenzhen ysstech info-tech, dongxing, and east money information all increased by over 5%.
Express News | Hubei Biocause Pharmaceutical: Recently, the company's operational situation and the internal and external operating environment have not undergone significant changes.
No Data